Somatostatin and cognitive function in neurodegenerative disorders

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 34-46

  Tuboly, Gábor ^a   Vécsei, László ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Alzheimer's disease; Animal models; Cognition; Huntington's disease; Learning; Memory; Parkinson's disease; Somatostatin

Indexed keywords

1 [3 [N (5 BROMO 2 PYRIDYL) N (3, 4 DICHLOROBENZYL) AMINO] PROPYL] 3 [3 (4 IMIDAZOLYL) PROPYL] THIOUREA; 1 [3 [N (5 BROMO 2 PYRIDYL) N (3,4 DICHLOROBENZYL)AMINO]PROPYL] 3 [3 (4 IMIDAZOLYL)PROPYL]THIOUREA; 4 AMINOBUTYRIC ACID; ACQ090; CORTISTATIN; FK962; FR121196; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; L 087; L 591; L 778; L 779; L 796; L 797; L 803; L 976; MERCAPTAMINE; N (4 ACETYL 1 PIPERAZINYL) 4 FLUOROBENZAMIDE; OCTREOTIDE; SCOPOLAMINE; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BEHAVIOR; COGNITION; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; LEARNING; MEMORY; NONHUMAN; PARKINSON DISEASE;

EID: 84875015702     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955713804484794     Document Type: Article

References (169)

1. Brazeau, P.; Vale, W.; Burgus, R.; Ling, N.; Butcher, M.; Rivier, J.; Guillemin, R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science, 1973, 179(4068), 77-79.
2. Pradayrol, L.; Jörnvall, H.; Mutt, V.; Ribet, A. N-terminally extended somatostatin: The primary structure of somatostatin-28. FEBS Lett., 1980, 109(1), 55-58.
3. Goodman, R. H.; Lund, P. K.; Jacobs, J. W.; Habener, J. F. Preprosomatostatins. Products of cell-free translations of messenger RNAs from anglerfish islets. J. Biol. Chem., 1980, 255(14), 6549-6552.
4. Patel, Y. C.; O'Neil, W. Peptides derived from cleavage of prosomatostatin at carboxyl-and amino-terminal segments. Characterization of tissue and secreted forms in the rat. J. Biol. Chem., 1988, 263(2), 745-751.
5. Bersani, M.; Thim, L.; Baldissera, F. G.; Holst, J. J. Prosomatostatin 1-64 is a major product of somatostatin gene expression in pancreas and gut. J. Biol. Chem., 1989, 264(18), 10633-10636.
6. Arimura, A.; Sato, H.; Dupont, A.; Nishi, N.; Schally, A. V. Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. Science, 1975, 189(4207), 1007-1009.
7. Dubois, M. P. Immunoreactive somatostatin is present in discrete cells of the endocrine pancreas. Proc. Natl. Acad. Sci. U.S. A, 1975, 72(4), 1340-1343.
8. Hokfelt, T.; Johansson, O.; Efendic, S.; Luft, R.; Arimura, A. Are there somatostatin-containing nerves in the rat gut? Immunohistochemical evidence for a new type of peripheral nerves. Experientia, 1975, 31(7), 852-854.
9. Pelletier, G.; Leclerc, R.; Arimura, A.; Schally, A. V. Letter: Immunohistochemical localization of somatostatin in the rat pancreas. J. Histochem. Cytochem., 1975, 23(9), 699-702.
10. Patel, Y. C.; Reichlin, S. Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat. Endocrinology, 1978, 102(2), 523-530.
11. Finley, J. C.; Maderdrut, J. L.; Roger, L. J.; Petrusz, P. The immunocytochemical localization of somatostatin-containing neurons in the rat central nervous system. Neuroscience, 1981, 6(11), 2173-2192.
12. Reichlin, S. Somatostatin. N. Engl. J. Med., 1983, 309(24), 1495-1501.
13. Reichlin, S. Somatostatin (second of two parts). N. Engl. J. Med., 1983, 309(25), 1556-1563.
14. Johansson, O.; Hokfelt, T.; Elde, R. P. Immunohistochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat. Neuroscience, 1984, 13(2), 265-339.
15. Aguila, M. C.; Dees, W. L.; Haensly, W. E.; McCann, S. M. Evidence that somatostatin is localized and synthesized in lymphoid organs. Proc. Natl. Acad. Sci. U.S. A, 1991, 88(24), 11485-11489.
16. Viollet, C.; Lepousez, G.; Loudes, C.; Videau, C.; Simon, A.; Epelbaum, J. Somatostatinergic systems in brain: networks and functions. Mol. Cell Endocrinol., 2008, 286(1-2), 75-87.
17. Lepousez, G.; Csaba, Z.; Bernard, V.; Loudes, C.; Videau, C.; Lacombe, J.; Epelbaum, J.; Viollet, C. Somatostatin interneurons delineate the inner part of the external plexiform layer in the mouse main olfactory bulb. J. Comp Neurol., 2010, 518(11), 1976-1994.
18. Lepousez, G.; Mouret, A.; Loudes, C.; Epelbaum, J.; Viollet, C. Somatostatin contributes to in vivo gamma oscillation modulation and odor discrimination in the olfactory bulb. J. Neurosci., 2010, 30(3), 870-875.
19. Epelbaum, J.; Guillou, J. L.; Gastambide, F.; Hoyer, D.; Duron, E.; Viollet, C. Somatostatin, Alzheimer's disease and cognition: an old story coming of age? Prog. Neurobiol., 2009, 89(2), 153-161.
20. Gonzalez, B. J.; Leroux, P.; Bodenant, C.; Laquerriere, A.; Coy, D. H.; Vaudry, H. Ontogeny of somatostatin receptors in the rat brain: biochemical and autoradiographic study. Neuroscience, 1989, 29(3), 629-644.
21. Sirviö, J.; Jolkkonen, J.; Pitkanen, A.; Riekkinen, P. J. Age dependence of somatostatin levels and somatostatin binding in the rat brain. Comp Biochem. Physiol A Comp Physiol, 1987, 87(2), 355-357.
22. Leroux, P.; Bodenant, C.; Bologna, E.; Gonzalez, B.; Vaudry, H. Transient expression of somatostatin receptors in the brain during development. Ciba Found. Symp., 1995, 190, 127-137.
23. Yacubova, E.; Komuro, H. Stage-specific control of neuronal migration by somatostatin. Nature, 2002, 415(6867), 77-81.
24. Stanic, D.; Malmgren, H.; He, H.; Scott, L.; Aperia, A.; Hokfelt, T. Developmental changes in frequency of the ciliary somatostatin receptor 3 protein. Brain Res., 2009, 1249, 101-112.
25. Goodyer, C. G.; Grigorakis, S. I.; Patel, Y. C.; Kumar, U. Developmental changes in the expression of somatostatin receptors (1-5) in the brain, hypothalamus, pituitary and spinal cord of the human fetus. Neuroscience, 2004, 125(2), 441-448.
26. Le, V., V; Kaindl, A. M.; Verney, C.; Csaba, Z.; Peineau, S.; Olivier, P.; Adle-Biassette, H.; Leterrier, C.; Vitalis, T.; Renaud, J.; Dargent, B.; Gressens, P.; Dournaud, P. The somatostatin 2A receptor is enriched in migrating neurons during rat and human brain development and stimulates migration and axonal outgrowth. PLoS. One., 2009, 4(5), e5509-
27. Rens-Domiano, S.; Reisine, T. Structural analysis and functional role of the carbohydrate component of somatostatin receptors. J. Biol. Chem., 1991, 266(30), 20094-20102.
28. Rens-Domiano, S.; Reisine, T. Biochemical and functional properties of somatostatin receptors. J. Neurochem., 1992, 58(6), 1987-1996.
29. Hannon, J. P.; Nunn, C.; Stolz, B.; Bruns, C.; Weckbecker, G.; Lewis, I.; Troxler, T.; Hurth, K.; Hoyer, D. Drug design at peptide receptors: somatostatin receptor ligands. J. Mol. Neurosci., 2002, 18(1-2), 15-27.
30. Olias, G.; Viollet, C.; Kusserow, H.; Epelbaum, J.; Meyerhof, W. Regulation and function of somatostatin receptors. J. Neurochem., 2004, 89(5), 1057-1091.
31. Siehler, S.; Nunn, C.; Hannon, J.; Feuerbach, D.; Hoyer, D. Pharmacological profile of somatostatin and cortistatin receptors. Mol. Cell Endocrinol., 2008, 286(1-2), 26-34.
32. Córdoba-Chacón, J.; Gahete, M. D.; Duran-Prado, M.; Pozo-Salas, A. I.; Malagon, M. M.; Gracia-Navarro, F.; Kineman, R. D.; Luque, R. M.; Castano, J. P. Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol. Life Sci., 2010, 67(7), 1147-1163.
33. Reisine, T.; Bell, G. I. Molecular properties of somatostatin receptors. Neuroscience, 1995, 67(4), 777-790.
34. Jiang, N.; Furue, H.; Katafuchi, T.; Yoshimura, M. Somatostatin directly inhibits substantia gelatinosa neurons in adult rat spinal dorsal horn in vitro. Neurosci. Res., 2003, 47(1), 97-107.
35. Baraban, S. C.; Tallent, M. K. Interneuron Diversity series: Interneuronal neuropeptides--endogenous regulators of neuronal excitability. Trends Neurosci., 2004, 27(3), 135-142.
36. Meis, S.; Sosulina, L.; Schulz, S.; Hollt, V.; Pape, H. C. Mechanisms of somatostatin-evoked responses in neurons of the rat lateral amygdala. Eur. J. Neurosci., 2005, 21(3), 755-762.
37. Viana, F.; Hille, B. Modulation of high voltage-activated calcium channels by somatostatin in acutely isolated rat amygdaloid neurons. J. Neurosci., 1996, 16(19), 6000-6011.
38. Baraban, S. C.; Tallent, M. K. Interneuron Diversity series: Interneuronal neuropeptides--endogenous regulators of neuronal excitability. Trends Neurosci., 2004, 27(3), 135-142.
39. Galarraga, E.; Vilchis, C.; Tkatch, T.; Salgado, H.; Tecuapetla, F.; Perez-Rosello, T.; Perez-Garci, E.; Hernandez-Echeagaray, E.; Surmeier, D. J.; Bargas, J. Somatostatinergic modulation of firing pattern and calcium-activated potassium currents in medium spiny neostriatal neurons. Neuroscience, 2007, 146(2), 537-554.
40. Cervia, D.; Casini, G.; Bagnoli, P. Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol. Cell Endocrinol., 2008, 286(1-2), 112-122.
41. Reisine, T. Somatostatin receptors. Am. J. Physiol, 1995, 269 (6 Pt 1), G813-G820.
42. Momiyama, T.; Zaborszky, L. Somatostatin presynaptically inhibits both GABA and glutamate release onto rat basal forebrain cholinergic neurons. J. Neurophysiol., 2006, 96(2), 686-694.
43. Grilli, M.; Raiteri, L.; Pittaluga, A. Somatostatin inhibits glutamate release from mouse cerebrocortical nerve endings through presynaptic sst2 receptors linked to the adenylyl cyclase-protein kinase A pathway. Neuropharmacology, 2004, 46(3), 388-396.
44. Lanneau, C.; Peineau, S.; Petit, F.; Epelbaum, J.; Gardette, R. Somatostatin modulation of excitatory synaptic transmission between periventricular and arcuate hypothalamic nuclei in vitro. J. Neurophysiol., 2000, 84(3), 1464-1474.
45. Nakata, A.; Saito, H.; Nishiyama, N. Facilitatory role of somatostatin via muscarinic cholinergic system in the generation of long-term potentiation in the rat dentate gyrus in vivo. Brain Res., 1996, 723 (1-2), 135-140.
46. Peineau, S.; Potier, B.; Petit, F.; Dournaud, P.; Epelbaum, J.; Gardette, R. AMPA-sst2 somatostatin receptor interaction in rat hypothalamus requires activation of NMDA and/or metabotropic glutamate receptors and depends on intracellular calcium. J. Physiol, 2003, 546(Pt 1), 101-117.
47. Dutar, P.; Vaillend, C.; Viollet, C.; Billard, J. M.; Potier, B.; Carlo, A. S.; Ungerer, A.; Epelbaum, J. Spatial learning and synaptic hippocampal plasticity in type 2 somatostatin receptor knock-out mice. Neuroscience, 2002, 112(2), 455-466.
48. Cammalleri, M.; Cervia, D.; Dal Monte, M.; Martini, D.; Langenegger, D.; Fehlmann, D.; Feuerbach, D.; Pavan, B.; Hoyer, D.; Bagnoli, P. Compensatory changes in the hippocampus of somatostatin knockout mice: upregulation of somatostatin receptor 2 and its function in the control of bursting activity and synaptic transmission. Eur. J. Neurosci., 2006, 23(9), 2404-2422.
49. Moneta, D.; Richichi, C.; Aliprandi, M.; Dournaud, P.; Dutar, P.; Billard, J. M.; Carlo, A. S.; Viollet, C.; Hannon, J. P.; Fehlmann, D.; Nunn, C.; Hoyer, D.; Epelbaum, J.; Vezzani, A. Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. Eur. J. Neurosci., 2002, 16(5), 843-849.
50. Leresche, N.; Asprodini, E.; Emri, Z.; Cope, D. W.; Crunelli, V. Somatostatin inhibits GABAergic transmission in the sensory thalamus via presynaptic receptors. Neuroscience, 2000, 98(3), 513-522.
51. Epelbaum, J. Somatostatin in the central nervous system: physiology and pathological modifications. Prog. Neurobiol., 1986, 27(1), 63-100.
52. Lanneau, C.; Bluet-Pajot, M. T.; Zizzari, P.; Csaba, Z.; Dournaud, P.; Helboe, L.; Hoyer, D.; Pellegrini, E.; Tannenbaum, G. S.; Epelbaum, J.; Gardette, R. Involvement of the Sst1 somatostatin receptor subtype in the intrahypothalamic neuronal network regulating growth hormone secretion: an in vitro and in vivo antisense study. Endocrinology, 2000, 141(3), 967-979.
53. Zheng, H.; Bailey, A.; Jiang, M. H.; Honda, K.; Chen, H. Y.; Trumbauer, M. E.; Van der Ploeg, L. H.; Schaeffer, J. M.; Leng, G.; Smith, R. G. Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons. Mol. Endocrinol., 1997, 11(11), 1709-1717.
54. Raynor, K.; Reisine, T. Somatostatin receptors. Crit Rev. Neurobiol., 1992, 6(4), 273-289.
55. Vécsei, L.; Widerlöv, E. Preclinical and clinical studies with somatostatin related to the central nervous system. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1990, 14(4), 473-502.
56. Siler, T. M.; VandenBerg, G.; Yen, S. S.; Brazeau, P.; Vale, W.; Guillemin, R. Inhibition of growth hormone release in humans by somatostatin. J. Clin. Endocrinol. Metab, 1973, 37(4), 632-634.
57. Havlicek, V.; Rezek, M.; Friesen, H. Somatostatin and thyrotropin releasing hormone: central effect on sleep and motor system. Pharmacol. Biochem. Behav., 1976, 4(4), 455-459.
58. Vécsei, L.; Schwarzberg, H.; Telegdy, G. Comparative studies with linear and cyclic somatostatin on the self-stimulation of rats. Acta Physiol Acad. Sci. Hung., 1982, 60(3), 165-168.
59. Vécsei, L.; Bollók, I.; Telegdy, G. Comparative studies with cyclic and linear somatostatin on active avoidance behavior and openfield activity in rats. Acta Physiol Hung., 1983, 61(1-2), 43-49.
60. Vécsei, L.; Bollók, I.; Telegdy, G. The effect of linear somatostatin on the active avoidance behavior and open-field activity on haloperidol, phenoxybenzamine and atropine pretreated rats. Acta Physiol Hung., 1983, 62(3-4), 205-211.
61. Vécsei, L.; Bollók, I.; Telegdy, G. Intracerebroventricular somatostatin attenuates electroconvulsive shock-induced amnesia in rats. Peptides, 1983, 4(3), 293-295.
62. Vécsei, L.; Schwarzberg, H.; Telegdy, G. The effect of somatostatin on self-stimulation behavior in atropine-and methysergide-pretreated rats. Eur. J. Pharmacol., 1983, 91(1), 89-93.
63. Vécsei, L.; Bollók, I.; Varga, J.; Penke, B.; Telegdy, G. Effect of somatostatin and its fragments on turning behavior induced by unilateral substantia nigra lesion in the rat. Acta Physiol Hung., 1984, 64(2), 157-162.
64. Vécsei, L.; Bollók, I.; Varga, J.; Penke, B.; Telegdy, G. The effects of somatostatin, its fragments and an analog on electroconvulsive shock-induced amnesia in rats. Neuropeptides, 1984, 4(2), 137-143.
65. Vécsei, L.; Király, C.; Bollók, I.; Nagy, A.; Varga, J.; Penke, B.; Telegdy, G. Comparative studies with somatostatin and cysteamine in different behavioral tests on rats. Pharmacol. Biochem. Behav., 1984, 21(6), 833-837.
66. Vécsei, L.; Widerlöv, E. Effects of intracerebroventricularly administered somatostatin on passive avoidance, shuttle-box behavior and open-field activity in rats. Neuropeptides, 1988, 12(4), 237-242.
67. Vécsei, L.; Pavo, I.; Zsigo, J.; Penke, B.; Widerlov, E. Comparative studies of somatostatin-14 and some of its fragments on passive avoidance behavior, open field activity and on barrel rotation phenomenon in rats. Peptides, 1989, 10(6), 1153-1157.
68. Vécsei, L.; Widerlöv, E.; Alling, C.; Zsigo, J.; Pavo, I.; Penke, B. Somatostatin28(15-28), but not somatostatin28(1-12), affects central monoaminergic neurotransmission in rats. Neuropeptides, 1990, 16(4), 181-186.
69. Bakhit, C.; Swerdlow, N. Behavioral changes following central injection of cysteamine in rats. Brain Res., 1986, 365(1), 159-163.
70. Haroutunian, V.; Mantin, R.; Campbell, G. A.; Tsuboyama, G. K.; Davis, K. L. Cysteamine-induced depletion of central somatostatinlike immunoactivity: effects on behavior, learning, memory and brain neurochemistry. Brain Res., 1987, 403(2), 234-242.
71. Schettini, G.; Florio, T.; Magri, G.; Grimaldi, M.; Meucci, O.; Landolfi, E.; Marino, A. Somatostatin and SMS 201-995 reverse the impairment of cognitive functions induced by cysteamine depletion of brain somatostatin. Eur. J. Pharmacol., 1988, 151(3), 399-407.
72. DeNoble, V. J.; Hepler, D. J.; Barto, R. A. Cysteamine-induced depletion of somatostatin produces differential cognitive deficits in rats. Brain Res., 1989, 482(1), 42-48.
73. Kungel, M.; Koch, M.; Friauf, E. Cysteamine impairs the development of the acoustic startle response in rats: possible role of somatostatin. Neurosci. Lett., 1996, 202(3), 181-184.
74. Fendt, M.; Koch, M.; Schnitzler, H. U. Somatostatin in the pontine reticular formation modulates fear potentiation of the acoustic startle response: an anatomical, electrophysiological, and behavioral study. J. Neurosci., 1996, 16(9), 3097-3103.
75. Feifel, D.; Minor, K. L. Cysteamine blocks amphetamine-induced deficits in sensorimotor gating. Pharmacol. Biochem. Behav., 1997, 58(3), 689-693.
76. Fitzgerald, L. W.; Dokla, C. P. Morris water task impairment and hypoactivity following cysteamine-induced reductions of somatostatinlike immunoreactivity. Brain Res., 1989, 505(2), 246-250.
77. Yamazaki, M.; Matsuoka, N.; Maeda, N.; Ohkubo, Y.; Yamaguchi, I. FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action. J. Pharmacol. Exp. Ther., 1996, 279(3), 1157-1173.
78. Tokita, K.; Inoue, T.; Yamazaki, S.; Wang, F.; Yamaji, T.; Matsuoka, N.; Mutoh, S. FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur. J. Pharmacol., 2005, 527(1-3), 111-120.
79. Guillou, J. L.; Micheau, J.; Jaffard, R. The opposite effects of cysteamine on the acquisition of two different tasks in mice are associated with bidirectional testing-induced changes in hippocampal adenylyl cyclase activity. Behav. Neurosci., 1998, 112(4), 900-908.
80. Guillou, J. L.; Micheau, J.; Jaffard, R. Intrahippocampal injections of cysteamine improve the retention of a bar-pressing task in mice. Behav. Brain Res., 1999, 103(1), 113-117.
81. Matsuoka, N.; Maeda, N.; Yamaguchi, I.; Satoh, M. Possible involvement of brain somatostatin in the memory formation of rats and the cognitive enhancing action of FR121196 in passive avoidance task. Brain Res., 1994, 642(1-2), 11-19.
82. Romanova, G. A.; Karganov, M. Y.; Kadar, T.; Telegdy, G. The effects of somatostatin and somatostatin antiserum on the retention of passive avoidance behavior after neofrontal decortication in rats. Physiol Behav., 1990, 47(5), 1035-1036.
83. Matsuoka, N.; Aigner, T. G. FK960 [N-(4-acetyl-1-piperazinyl)-pfluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine. J. Pharmacol. Exp. Ther., 1997, 280(3), 1201-1209.
84. Tokita, K.; Yamazaki, S.; Yamazaki, M.; Matsuoka, N.; Mutoh, S. Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats. Pharmacol. Biochem. Behav., 2002, 73(3), 511-519.
85. Tokita, K.; Inoue, T.; Yamazaki, S.; Wang, F.; Yamaji, T.; Matsuoka, N.; Mutoh, S. FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur. J. Pharmacol., 2005, 527(1-3), 111-120.
86. Hoyer, D.; Lubbert, H.; Bruns, C. Molecular pharmacology of somatostatin receptors. Naunyn Schmiedebergs Arch. Pharmacol., 1994, 350(5), 441-453.
87. Semenova, S.; Hoyer, D.; Geyer, M. A.; Markou, A. Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats. Neuropeptides, 2010, 44(5), 421-429.
88. Gastambide, F.; Viollet, C.; Lepousez, G.; Epelbaum, J.; Guillou, J. L. Hippocampal SSTR4 somatostatin receptors control the selection of memory strategies. Psychopharmacology (Berl), 2009, 202(1-3), 153-163.
89. Zeyda, T.; Diehl, N.; Paylor, R.; Brennan, M. B.; Hochgeschwender, U. Impairment in motor learning of somatostatin null mutant mice. Brain Res., 2001, 906(1-2), 107-114.
90. Dutar, P.; Vaillend, C.; Viollet, C.; Billard, J. M.; Potier, B.; Carlo, A. S.; Ungerer, A.; Epelbaum, J. Spatial learning and synaptic hippocampal plasticity in type 2 somatostatin receptor knock-out mice. Neuroscience, 2002, 112(2), 455-466.
91. Zeyda, T.; Hochgeschwender, U. Null mutant mouse models of somatostatin and cortistatin, and their receptors. Mol. Cell Endocrinol., 2008, 286(1-2), 18-25.
92. Olias, G.; Viollet, C.; Kusserow, H.; Epelbaum, J.; Meyerhof, W. Regulation and function of somatostatin receptors. J. Neurochem., 2004, 89(5), 1057-1091.
93. de Lecea, L. Cortistatin--functions in the central nervous system. Mol. Cell Endocrinol., 2008, 286(1-2), 88-95.
94. Einstein, E. B.; Patterson, C. A.; Hon, B. J.; Regan, K. A.; Reddi, J.; Melnikoff, D. E.; Mateer, M. J.; Schulz, S.; Johnson, B. N.; Tallent, M. K. Somatostatin signaling in neuronal cilia is critical for object recognition memory. J. Neurosci., 2010, 30(12), 4306-4314.
95. Crusio, W. E. Flanking gene and genetic background problems in genetically manipulated mice. Biol. Psychiatry, 2004, 56(6), 381-385.
96. Frye, M. A.; Pazzaglia, P. J.; George, M. S.; Luckenbaugh, D. A.; Vanderham, E.; Davis, C. L.; Rubinow, D. R.; Post, R. M. Low CSF somatostatin associated with response to nimodipine in patents with affective illness. Biol. Psychiatry, 2003, 53(2), 180-183.
97. Braak, H.; Braak, E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol., 1991, 1(3), 213-216.
98. Selkoe, D. J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimers. Dis., 2001, 3(1), 75-80.
99. Hsiao, K.; Chapman, P.; Nilsen, S.; Eckman, C.; Harigaya, Y.; Younkin, S.; Yang, F.; Cole, G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science, 1996, 274(5284), 99-102.
100. Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev., 2001, 81(2), 741-766.
101. Hardy, J. A.; Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256(5054), 184-185.
102. Selkoe, D. J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem., 1996, 271(31), 18295-18298.
103. Scheuner, D.; Eckman, C.; Jensen, M.; Song, X.; Citron, M.; Suzuki, N.; Bird, T. D.; Hardy, J.; Hutton, M.; Kukull, W.; Larson, E.; Levy-Lahad, E.; Viitanen, M.; Peskind, E.; Poorkaj, P.; Schellenberg, G.; Tanzi, R.; Wasco, W.; Lannfelt, L.; Selkoe, D.; Younkin, S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med., 1996, 2(8), 864-870.
104. Weiner, M. F.; Svetlik, D.; Risser, R. C. What depressive symptoms are reported in Alzheimer's patients? Int. J. Geriatr. Psychiatry, 1997, 12(6), 648-652.
105. Davies, P.; Katzman, R.; Terry, R. D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature, 1980, 288(5788), 279-280.
106. Beal, M. F.; Benoit, R.; Mazurek, M. F.; Bird, E. D.; Martin, J. B. Somatostatin-28(1-12)-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Brain Res., 1986, 368(2), 380-383.
107. Davis, K. L.; Davidson, M.; Yang, R. K.; Davis, B. M.; Siever, L. J.; Mohs, R. C.; Ryan, T.; Coccaro, E.; Bierer, L.; Targum, S. D. CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects. Biol. Psychiatry, 1988, 24(6), 710-712.
108. Bissette, G.; Myers, B. Somatostatin in Alzheimer's disease and depression. Life Sci., 1992, 51(18), 1389-1410.
109. Nemeroff, C. B.; Knight, D. L.; Bissette, G. Somatostatin: a neuropeptide system pathologically altered in Alzheimer's disease and depression. Clin. Neuropharmacol., 1992, 15 Suppl 1 Pt A311A-312A.
110. Molchan, S. E.; Hill, J. L.; Martinez, R. A.; Lawlor, B. A.; Mellow, A. M.; Rubinow, D. R.; Bissette, G.; Nemeroff, C. B.; Sunderland, T. CSF somatostatin in Alzheimer's disease and major depression: relationship to hypothalamic-pituitary-adrenal axis and clinical measures. Psychoneuroendocrinology, 1993, 18(7), 509-519.
111. Bissette, G.; Cook, L.; Smith, W.; Dole, K. C.; Crain, B.; Nemeroff, C. B. Regional Neuropeptide Pathology in Alzheimer's Disease: Corticotropin-Releasing Factor and Somatostatin. J. Alzheimers. Dis., 1998, 1(2), 91-105.
112. Nilsson, C. L.; Brinkmalm, A.; Minthon, L.; Blennow, K.; Ekman, R. Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Peptides, 2001, 22(12), 2105-2112.
113. Kumar, U. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis. Neuroscience, 2005, 134(2), 525-538.
114. Dournaud, P.; Delaere, P.; Hauw, J. J.; Epelbaum, J. Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer's disease. Neurobiol. Aging, 1995, 16(5), 817-823.
115. Ramos, B.; Baglietto-Vargas, D.; del Rio, J. C.; Moreno-Gonzalez, I.; Santa-Maria, C.; Jimenez, S.; Caballero, C.; Lopez-Tellez, J. F.; Khan, Z. U.; Ruano, D.; Gutierrez, A.; Vitorica, J. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol. Aging, 2006, 27(11), 1658-1672.
116. Saito, T.; Iwata, N.; Tsubuki, S.; Takaki, Y.; Takano, J.; Huang, S. M.; Suemoto, T.; Higuchi, M.; Saido, T. C. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat. Med., 2005, 11(4), 434-439.
117. Nag, S.; Yee, B. K.; Tang, F. Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of beta-amyloid (1-40). Brain Res. Bull., 1999, 50(4), 251-262.
118. Hervas-Aguilar, A.; Puebla-Jimenez, L.; Burgos-Ramos, E.; Aguado-Llera, D.; Arilla-Ferreiro, E. Effects of single and continuous administration of amyloid beta-peptide (25-35) on adenylyl cyclase activity and the somatostatinergic system in the rat frontal and parietal cortex. Neuroscience, 2005, 135(1), 181-190.
119. Aguado-Llera, D.; Arilla-Ferreiro, E.; Campos-Barros, A.; Puebla-Jimenez, L.; Barrios, V. Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of beta-amyloid-treated rats. J. Neurochem., 2005, 92(3), 607-615.
120. Burgos-Ramos, E.; Hervas-Aguilar, A.; Puebla-Jimenez, L.; Boyano-Adanez, M. C.; Arilla-Ferreiro, E. Chronic but not acute intracerebroventricular administration of amyloid beta-peptide(25-35) decreases somatostatin content, adenylate cyclase activity, somatostatin-induced inhibition of adenylate cyclase activity, and adenylate cyclase I levels in the rat hippocampus. J. Neurosci. Res., 2007, 85(2), 433-442.
121. Aguado-Llera, D.; Arilla-Ferreiro, E.; Chowen, J. A.; Argente, J.; Puebla-Jimenez, L.; Frago, L. M.; Barrios, V. 17Beta-estradiol protects depletion of rat temporal cortex somatostatinergic system by beta-amyloid. Neurobiol. Aging, 2007, 28(9), 1396-1409.
122. Beal, M. F.; Mazurek, M. F.; Tran, V. T.; Chattha, G.; Bird, E. D.; Martin, J. B. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science, 1985, 229(4710), 289-291.
123. Whitford, C.; Candy, J.; Edwardson, J.; Perry, R. Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases. J. Neurol. Sci., 1988, 86(1), 13-18.
124. Krantic, S.; Robitaille, Y.; Quirion, R. Deficits in the somatostatin SS1 receptor sub-type in frontal and temporal cortices in Alzheimer's disease. Brain Res., 1992, 573(2), 299-304.
125. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 1993, 72(6), 971-983.
126. Cooper, J. K.; Schilling, G.; Peters, M. F.; Herring, W. J.; Sharp, A. H.; Kaminsky, Z.; Masone, J.; Khan, F. A.; Delanoy, M.; Borchelt, D. R.; Dawson, V. L.; Dawson, T. M.; Ross, C. A. Truncated Nterminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet., 1998, 7(5), 783-790.
127. Hahn-Barma, V.; Deweer, B.; Durr, A.; Dode, C.; Feingold, J.; Pillon, B.; Agid, Y.; Brice, A.; Dubois, B. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. J. Neurol. Neurosurg. Psychiatry, 1998, 64(2), 172-177.
128. Lawrence, A. D.; Hodges, J. R.; Rosser, A. E.; Kershaw, A.; ffrench-Constant, C.; Rubinsztein, D. C.; Robbins, T. W.; Sahakian, B. J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain, 1998, 121 (Pt 7)1329-1341.
129. Snowden, J. S.; Craufurd, D.; Thompson, J.; Neary, D. Psychomotor, executive, and memory function in preclinical Huntington's disease. J. Clin. Exp. Neuropsychol., 2002, 24(2), 133-145.
130. Van Raamsdonk, J. M.; Pearson, J.; Slow, E. J.; Hossain, S. M.; Leavitt, B. R.; Hayden, M. R. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci., 2005, 25(16), 4169-4180.
131. Cramer, H.; Kohler, J.; Oepen, G.; Schomburg, G.; Schroter, E. Huntington's chorea--measurements of somatostatin, substance P and cyclic nucleotides in the cerebrospinal fluid. J. Neurol., 1981, 225(3), 183-187.
132. Aronin, N.; Cooper, P. E.; Lorenz, L. J.; Bird, E. D.; Sagar, S. M.; Leeman, S. E.; Martin, J. B. Somatostatin is increased in the basal ganglia in Huntington disease. Ann. Neurol., 1983, 13(5), 519-526.
133. Nemeroff, C. B.; Youngblood, W. W.; Manberg, P. J.; Prange, A. J., Jr.; Kizer, J. S. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science, 1983, 221(4614), 972-975.
134. Beal, M. F.; Bird, E. D.; Langlais, P. J.; Martin, J. B. Somatostatin is increased in the nucleus accumbens in Huntington's disease. Neurology, 1984, 34(5), 663-666.
135. Manberg, P. J.; Nemeroff, C. B.; Bissette, G.; Widerlov, E.; Youngblood, W. W.; Kizer, J. S.; Prange, A. J., Jr. Neuropeptides in CSF and post-mortem brain tissue of normal controls, schizophrenics and Huntington's choreics. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1985, 9(1), 97-108.
136. Marshall, P. E.; Landis, D. M. Huntington's disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes. Brain Res., 1985, 329(1-2), 71-82.
137. Coyle, J. T.; Schwarcz, R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature, 1976, 263(5574), 244-246.
138. Beal, M. F.; Kowall, N. W.; Ellison, D. W.; Mazurek, M. F.; Swartz, K. J.; Martin, J. B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature, 1986, 321(6066), 168-171.
139. Beal, M. F.; Ferrante, R. J.; Swartz, K. J.; Kowall, N. W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci., 1991, 11(6), 1649-1659.
140. Vécsei, L.; Beal, M. F. Comparative behavioral and neurochemical studies with striatal kainic acid-or quinolinic acid-lesioned rats. Pharmacol. Biochem. Behav., 1991, 39(2), 473-478.
141. Palacios, J. M.; Rigo, M.; Chinaglia, G.; Probst, A. Reduced density of striatal somatostatin receptors in Huntington's chorea. Brain Res., 1990, 522(2), 342-346.
142. Shults, C.; Steardo, L.; Barone, P.; Mohr, E.; Juncos, J.; Serrati, C.; Fedio, P.; Tamminga, C. A.; Chase, T. N. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology, 1986, 36(8), 1099-1102.
143. Van Raamsdonk, J. M.; Pearson, J.; Bailey, C. D.; Rogers, D. A.; Johnson, G. V.; Hayden, M. R.; Leavitt, B. R. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J. Neurochem., 2005, 95(1), 210-220.
144. Dupont, E.; Christensen, S. E.; Hansen, A. P.; de Fine, O. B.; Orskov, H. Low cerebrospinal fluid somatostatin in Parkinson disease: an irreversible abnormality. Neurology, 1982, 32(3), 312-314.
145. Epelbaum, J.; Ruberg, M.; Moyse, E.; Javoy-Agid, F.; Dubois, B.; Agid, Y. Somatostatin and dementia in Parkinson's disease. Brain Res., 1983, 278(1-2), 376-379.
146. Cramer, H.; Wolf, A.; Rissler, K.; Weigel, K.; Ostertag, C. Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease. J. Neurol., 1985, 232(4), 219-222.
147. Beal, M. F.; Mazurek, M. F.; Martin, J. B. Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes. Brain Res., 1986, 397(2), 386-388.
148. Strittmatter, M. M.; Cramer, H. Parkinson's disease and dementia: clinical and neurochemical correlations. Neuroreport, 1992, 3(5), 413-416.
149. Strittmatter, M.; Hamann, G. F.; Strubel, D.; Cramer, H.; Schimrigk, K. Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa. J. Neural Transm., 1996, 103(5), 591-602.
150. Eve, D. J.; Nisbet, A. P.; Kingsbury, A. E.; Temlett, J.; Marsden, C. D.; Foster, O. J. Selective increase in somatostatin mRNA expression in human basal ganglia in Parkinson's disease. Brain Res. Mol. Brain Res., 1997, 50(1-2), 59-70.
151. Espino, A.; Calopa, M.; Ambrosio, S.; Ortola, J.; Peres, J.; Navarro, M. A. CSF somatostatin increase in patients with early parkinsonian syndrome. J. Neural Transm. Park Dis. Dement. Sect., 1995, 9(2-3), 189-196.
152. Arai, H.; Moroji, T.; Kosaka, K. Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer-type dementia. Neurosci. Lett., 1984, 52(1-2), 73-78.
153. Candy, J. M.; Gascoigne, A. D.; Biggins, J. A.; Smith, A. I.; Perry, R. H.; Perry, E. K.; McDermott, J. R.; Edwardson, J. A. Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer's disease. J. Neurol. Sci., 1985, 71(2-3), 315-323.
154. Francis, P. T.; Bowen, D. M.; Lowe, S. L.; Neary, D.; Mann, D. M.; Snowden, J. S. Somatostatin content and release measured in cerebral biopsies from demented patients. J. Neurol. Sci., 1987, 78(1), 1-16.
155. Whitford, C.; Candy, J.; Edwardson, J.; Perry, R. Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases. J. Neurol. Sci., 1988, 86(1), 13-18.
156. Poewe, W.; Benke, T.; Karamat, E.; Schelosky, L.; Wagner, M.; Sperk, G. CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 1990, 53(12), 1105-1106.
157. Nilsson, A.; Falth, M.; Zhang, X.; Kultima, K.; Skold, K.; Svenningsson, P.; Andren, P. E. Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease. Mol. Cell Proteomics., 2009, 8(5), 1094-1104.
158. Shiraishi, M.; Kobayashi, T.; Watanabe, H.; Kamo, T.; Hasegawa, Y. Serum somatostatin in early-stage Parkinson's disease. Acta Neurol. Scand., 2010, 121(4), 225-229.
159. Cotzias, G. C.; Papavasiliou, P. S.; Ginos, J. Z. Therapeutic approaches in Parkinson's disease: possible roles of growth hormone and somatostatin. Res. Publ. Assoc. Res. Nerv. Ment. Dis., 1976, 55, 305-315.
160. Dupont, E.; Hansen, A. P.; Juul-Jensen, P.; Lundbaek, K.; Magnussen, I.; de Fine, O. B. Somatostatin in the treatment of patients with extra-pyramidal disorders and patients with EEG abnormalities. Acta Neurol. Scand., 1978, 57(6), 488-493.
161. Raaphorst, J.; de Visser, M.; Linssen, W. H.; de Haan, R. J.; Schmand, B. The cognitive profile of amyotrophic lateral sclerosis: A meta-analysis. Amyotroph. Lateral. Scler., 2010, 11(1-2), 27-37.
162. Ringholz, G. M.; Appel, S. H.; Bradshaw, M.; Cooke, N. A.; Mosnik, D. M.; Schulz, P. E. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology, 2005, 65(4), 586-590.
163. Rusina, R.; Ridzon, P.; Kulist'ak, P.; Keller, O.; Bartos, A.; Buncova, M.; Fialova, L.; Koukolik, F.; Matej, R. Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study. Eur. J. Neurol., 2010, 17(1), 23-30.
164. Frank, B.; Haas, J.; Heinze, H. J.; Stark, E.; Munte, T. F. Relation of neuropsychological and magnetic resonance findings in amyotrophic lateral sclerosis: evidence for subgroups. Clin. Neurol. Neurosurg., 1997, 99(2), 79-86.
165. Pinkhardt, E. H.; van Elst, L. T.; Ludolph, A. C.; Kassubek, J. Amygdala size in amyotrophic lateral sclerosis without dementia: an in vivo study using MRI volumetry. BMC. Neurol., 2006, 6, 48.
166. Desai, J.; Swash, M. Extrapyramidal involvement in amyotrophic lateral sclerosis: backward falls and retropulsion. J. Neurol. Neurosurg. Psychiatry, 1999, 67(2), 214-216.
167. Katagiri, T.; Kuzirai, T.; Nihei, K.; Honda, K.; Sasaki, H.; Polak, J. M. Immunocytochemical study of Onuf's nucleus in amyotrophic lateral sclerosis. Jpn. J. Med., 1988, 27(1), 23-28.
168. Hartikainen, P.; Reinikainen, K. J.; Soininen, H.; Sirvio, J.; Soikkeli, R.; Riekkinen, P. J. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J. Neural Transm. Park Dis. Dement. Sect., 1992, 4(1), 53-68.
169. Nieto-Gonzalez, J. L.; Moser, J.; Lauritzen, M.; Schmitt-John, T.; Jensen, K. Reduced GABAergic inhibition explains cortical hyperexcitability in the wobbler mouse model of ALS. Cereb. Cortex, 2011, 21(3), 625-635.